Rituximab
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
Explore 12 assets in Diffuse Large B-Cell Lymphoma Of The Central Nervous System →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma Of The Central Nervous System
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Pomalidomide | Mayo Clinic | P1 | CCC |
| Dexasone | National Cancer Institute (NCI) | P1 | CC |
| Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer | National Cancer Institute (NCI) | P2 | CC |
| Ibrutinib | National Cancer Institute (NCI) | P1 | CC |
| Venetoclax | National Cancer Institute (NCI) | P1 | CC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CC |
| Diphenhydramine | National Cancer Institute (NCI) | P1 | CC |
+4 more in the Diffuse Large B-Cell Lymphoma Of The Central Nervous System cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NivolumabNational Cancer Institute (NCI)B
- PomalidomideMayo ClinicCCC
- DexasoneNational Cancer Institute (NCI)CC
- Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, DimerNational Cancer Institute (NCI)CC
- IbrutinibNational Cancer Institute (NCI)CC
Citation
Floatz Terminal. Rituximab in Diffuse Large B-Cell Lymphoma Of The Central Nervous System. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →